To better understand the impact of TNFAIP3 loss on MYD88L265P in DLBCL and WM, we first wanted to determine the frequency of MYD88 mutations in combination with TNFAIP3 genetic alterations. This evidence concerns the gene TNFAIP3 and diffuse large B-cell lymphoma.